stockrowRecursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Revenue
- +258.5%
- EPS
- +39.1%
- Free cash flow
- +33.8%
- Total debt
- −99.2%
Quarter to September 2026, against a year earlier
Follow RXRX
Alert me
Recursion Pharmaceuticals, Inc. (RXRX) Revenue
Recursion Pharmaceuticals, Inc.'s revenue for fiscal 2025 was $74.7M, up 26.9% from $58.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $68.2M. Over the past ten years it has ranged from $2.3M (fiscal 2019) to $74.7M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 6 consecutive fiscal years. Recursion Pharmaceuticals, Inc. ranks 112th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $74.7M | 26.92% |
| FY2024 | $58.8M | 32.00% |
| FY2023 | $44.6M | 11.88% |
| FY2022 | $39.8M | 291.46% |
| FY2021 | $10.2M | 156.89% |
| FY2020 | $4.0M | 70.85% |
| FY2019 | $2.3M | 0.00% |
| FY2019 | $2.3M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $18.6M | 141.88% |
| Jun 2026 | $7.7M | 18.51% |
| Mar 2026 | $6.5M | (81.79%) |
| Dec 2025 | $35.5M | 586.72% |
| 23 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| BHVN Biohaven Ltd. compare | $995.4M |
| ADMA ADMA Biologics Inc compare | $519.2M |
| VCEL Vericel Corporation compare | $324.2M |
| RXRX Recursion Pharmaceuticals, Inc. | $68.2M |
| PVLA Palvella Therapeutics, Inc. compare | $41.6M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $25.9M |
| CLDX Celldex Therapeutics, Inc. compare | $887.0K |
| PHVS Pharvaris N.V. compare | — |
| MBX MBX Biosciences, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on RXRX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement